申请人:HEIMANN Annekatrin
公开号:US20130158042A1
公开(公告)日:2013-06-20
This invention relates to compounds of formula I
their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R
1
, R
2
, R
3
, R
4
, Q have meanings given in the description.
这项发明涉及公式I的化合物,它们作为mGlu5受体活性的正向变构调节剂的用途,含有这些化合物的药物组合物,以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍,如精神分裂症或认知功能下降,如痴呆症或认知障碍的药剂的方法。R1,R2,R3,R4,Q在描述中给出了含义。